ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LGND Ligand Pharmaceuticals Incorporated

71.42
1.53 (2.19%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ligand Pharmaceuticals Incorporated NASDAQ:LGND NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.53 2.19% 71.42 68.95 74.37 72.17 69.51 69.89 115,870 00:57:14

Statement of Changes in Beneficial Ownership (4)

26/08/2020 12:11am

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FOEHR MATTHEW W
2. Issuer Name and Ticker or Trading Symbol

LIGAND PHARMACEUTICALS INC [ LGND ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President and COO
(Last)          (First)          (Middle)

3911 SORRENTO VALLEY BOULEVARD, STE 110
3. Date of Earliest Transaction (MM/DD/YYYY)

8/21/2020
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 8/21/2020  M  790 A$74.42 155413 D  
Common Stock 8/21/2020  M  7225 (1)A$14.47 162638 D  
Common Stock 8/21/2020  S  7225 (1)D$112.8776 (2)155413 D  
Common Stock 8/24/2020  M  78 (1)A$21.92 155491 D  
Common Stock 8/24/2020  S  78 (1)D$110.89 155413 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy) $14.47 8/21/2020 8/21/2020 M     7225 (1)  (3)2/9/2022 Common Stock 7225 $0.0 0 D  
Employee Stock Option (right to buy) $21.92 8/24/2020 8/24/2020 M     78 (1)  (4)2/15/2023 Common Stock 78 $0.0 64547 D  
Employee Stock Option (right to buy) $74.42 8/21/2020 8/21/2020 M     790   (5)2/12/2024 Common Stock 790 $0.0 64210 D  

Explanation of Responses:
(1) The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 03, 2020, in accordance with Rule 10b5-1.
(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.26 to $114.36, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(3) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12.
(4) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
(5) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
FOEHR MATTHEW W
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO, CA 92121


President and COO

Signatures
By: Charles S. Berkman For: Matthew W. Foehr8/25/2020
**Signature of Reporting PersonDate

1 Year Ligand Pharmaceuticals Chart

1 Year Ligand Pharmaceuticals Chart

1 Month Ligand Pharmaceuticals Chart

1 Month Ligand Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock